These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 32942545)

  • 1. Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy.
    Wang Y; Jia A; Bi Y; Wang Y; Yang Q; Cao Y; Li Y; Liu G
    Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32942545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
    Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
    Front Immunol; 2020; 11():585214. PubMed ID: 33613512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Myeloid-Derived Suppressor Cells to Enhance the Antitumor Efficacy of Immune Checkpoint Blockade Therapy.
    Li X; Zhong J; Deng X; Guo X; Lu Y; Lin J; Huang X; Wang C
    Front Immunol; 2021; 12():754196. PubMed ID: 35003065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloid-Derived Suppressor Cells: A New and Pivotal Player in Colorectal Cancer Progression.
    Yin K; Xia X; Rui K; Wang T; Wang S
    Front Oncol; 2020; 10():610104. PubMed ID: 33384962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer.
    Li K; Shi H; Zhang B; Ou X; Ma Q; Chen Y; Shu P; Li D; Wang Y
    Signal Transduct Target Ther; 2021 Oct; 6(1):362. PubMed ID: 34620838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond.
    Zhao Y; Du J; Shen X
    Front Immunol; 2023; 14():1157537. PubMed ID: 37006306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives.
    Lu LC; Chang CJ; Hsu CH
    J Hepatocell Carcinoma; 2019; 6():71-84. PubMed ID: 31123667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy.
    Wu Y; Yi M; Niu M; Mei Q; Wu K
    Mol Cancer; 2022 Sep; 21(1):184. PubMed ID: 36163047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of targeting MDSCs in tumor microenvironment.
    Sui H; Dongye S; Liu X; Xu X; Wang L; Jin CQ; Yao M; Gong Z; Jiang D; Zhang K; Liu Y; Liu H; Jiang G; Su Y
    Front Immunol; 2022; 13():990463. PubMed ID: 36131911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.
    Parker KH; Beury DW; Ostrand-Rosenberg S
    Adv Cancer Res; 2015; 128():95-139. PubMed ID: 26216631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of T cells by myeloid-derived suppressor cells in cancer.
    Chen J; Ye Y; Liu P; Yu W; Wei F; Li H; Yu J
    Hum Immunol; 2017 Feb; 78(2):113-119. PubMed ID: 27939507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
    Dysthe M; Parihar R
    Adv Exp Med Biol; 2020; 1224():117-140. PubMed ID: 32036608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immunobiology of myeloid-derived suppressor cells in cancer.
    Motallebnezhad M; Jadidi-Niaragh F; Qamsari ES; Bagheri S; Gharibi T; Yousefi M
    Tumour Biol; 2016 Feb; 37(2):1387-406. PubMed ID: 26611648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Characterization of Myeloid-Derived Suppressor Cells in Tumor Microenvironment.
    Li Y; He H; Jihu R; Zhou J; Zeng R; Yan H
    Front Cell Dev Biol; 2021; 9():698532. PubMed ID: 34527668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer.
    Law AMK; Valdes-Mora F; Gallego-Ortega D
    Cells; 2020 Feb; 9(3):. PubMed ID: 32121014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloid-derived suppressor cells: The green light for myeloma immune escape.
    Malek E; de Lima M; Letterio JJ; Kim BG; Finke JH; Driscoll JJ; Giralt SA
    Blood Rev; 2016 Sep; 30(5):341-8. PubMed ID: 27132116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel therapeutic strategies targeting myeloid-derived suppressor cell immunosuppressive mechanisms for cancer treatment.
    Jou E; Chaudhury N; Nasim F
    Explor Target Antitumor Ther; 2024; 5(1):187-207. PubMed ID: 38464388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion.
    Lu J; Luo Y; Rao D; Wang T; Lei Z; Chen X; Zhang B; Li Y; Liu B; Xia L; Huang W
    Exp Hematol Oncol; 2024 Apr; 13(1):39. PubMed ID: 38609997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanomedicine Targeting Myeloid-Derived Suppressor Cells Enhances Anti-Tumor Immunity.
    Yang EL; Sun ZJ
    Adv Healthc Mater; 2024 Apr; 13(9):e2303294. PubMed ID: 38288864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.
    Fleming V; Hu X; Weber R; Nagibin V; Groth C; Altevogt P; Utikal J; Umansky V
    Front Immunol; 2018; 9():398. PubMed ID: 29552012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.